Clinical Trails

New Epilepsy Drugs in Development

Current Studies at Mid-Atlantic Epilepsy and Sleep Center:

Ongoing Clinical trials open for Enrollment at our Location

  1. Protocol Title: YKP3089C025
    Study Description: A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of CenobamateAdjunctive Therapy in Subjects with Primary Generalized Tonic-Clonic Seizures
    Targeted Population: 12- 60 years

  2. Protocol Title: YKP3089C039
    Study Description: A phase 1, open label pharmacokinetic dose escalation study ofCenobamate (YKP3089) in Pediatric Subjects with POS
    Targeted Population: 6-12 years (only 1 open slot)/ 4-6 years ( 6 open slots)

  3. Protocol Title: YKP3089C040
    Study Description: Open-Label Safety and Efficacy Study of Cenobamate(YKP3089) in Pediatric Subjects with Partial-onset (Focal) Seizures
    Targeted Population: 12- 17 years

  4. Protocol Title: YKP509C003
    Study Description: A Randomized, Double-blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Carisbamate (YKP509) as Adjunctive Treatment for Seizures Associated with Lennox-Gastaut Syndrome in Children and Adults, with Optional Open-Label Extension
    Targeted Population: 4-55 years

  5. Protocol Title: XPF-008-301
    Study Description: A Randomized, Double-Blind Placebo-controlled multicenter Phase 3 Study to Evaluate the safety tolerability and efficacy ofXEN1101 as adjunctive Therapy in focal -onset Epilepsy
    Targeted Population: ≥ 18 years

  6. Protocol Title: CVL-865-SZ-001
    Study Description: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Trial of CVL-865 as Adjunctive Therapy in Adults with Drug-Resistant Focal Onset Seizures (REALIZE)
    Targeted Population: 18- 75 years

  7. Protocol Title: 1042-TSC-3001
    Study Description: A phase 3, double blind randomized placebo-controlled trial of adjunctive Ganaxolone (GNX) treatment in children and Adults with Tuberous Sclerosis Complex (TSC) related Epilepsy (TRUSTTSC)
    Targeted Population: 1- 65 years

  8. Protocol Title: E2023-A001-304
    Study Description: A multicenter, double-blind, randomized, placebo-controlled, parallel-group study of Lorcaserin as adjunctive treatment in patients with Dravet Syndrome
    Targeted Population: age 2 years and older, Dravet Syndrome

  9. Protocol Title: E2023-A001-405
    Study Description: Extended access program and retrospective chart review for Lorcaserin in Dravet Syndrome and other refractory Epilepsies
    Targeted Population: age 2 years and older

  10. The Human Epilepsy Project 3: a prospective, observational study (no additional treatment as part of the study). The purpose of this study is to identify factors that can predict how patients with generalized epilepsy respond to a given seizure medication prescribed by their neurologist. The study team will gather different information from the patient over a period of 3 years or longer

This Is Only A Partial List. Please Contact Our Office If You Would Be Interested In Participating In One Of Our Studies.

Scroll to Top